Objective: The effect of polymers used in nanoparticle (NP) production on the formulation properties is one of the few studied issues. Therefore, this study aims to formulate flurbiprofen (FLB) loaded NPs with different molecular weight (Mw) PLGA and investigate the effect of Mw on NP character. One of the most important objectives is to provide a high anti-inflammatory effect with a low dose and the anti-inflammatory efficacy of the selected optimal formulation is to be determined by in vivo Hen's Egg Test on Chorioallantoic Membrane (HET-CAM) analysis that a new, popular and in vivo animal experiment alternative method. Significance: To determine the anti-inflammatory efficacy of the optimum formulation by HET-CAM analysis. To the best of our knowledge this is the first report on the in vivo anti-inflammatory evaluation of FLB loaded PLGA NP using the in vivo HET-CAM assay. Methods: Blank and FLB loaded PLGA NPs were prepared using a nanoprecipitation technique. The cell viability test for all formulation was performed with MTT in the NIH-3T3 mouse embryonic fibroblast cell line. The anti-inflammatory activity of optimum formulation (A6) was examined using the in vivo HET-CAM assay. Results: The particle sizes (PS) of the FLB loaded PLGA NPs were between 175 and 198 nm. The encapsulation efficiency (EE%) was a range of 82-93%. In vitro release of NPs showed extended release up to 144 hours. The release kinetics were fitted to the Peppas-Sahlin and Weibull models. The results showed that PS, PDI, EE% and release rates of NPs were directly related to the Mw of PLGA. There is no statistically significant difference in cell viability study was observed between blank and FLB loaded PLGA NPs. The in vivo anti-inflammatory activity results indicated that A6 coded formulation was showed significantly good anti-inflammatory potential at low dose. Conclusions: It could be concluded that FLB loaded NPs seem to be a promising extended release drug delivery system for oral administration with a low dose and high efficiency.
1 August 2021 in Journal of Drug Delivery Science and Technology
Ocular allergy is one of the most common disorders of the eye surface. Following diagnosis this condition is typically treated with preparations containing antihistamines. However, anatomy of the eye and its natural protective mechanisms create challenges for ocular drug delivery. Rapid elimination of antihistamine substances due to short residency times following application can lead to insufficient treatment of ocular allergies. With this in mind, the aim of this study was to prepare a controlled ocular delivery system to extend the retention time of olopatadine hydrochloride (OLO) and in doing so to reduce the need for frequent application. We developed extended-release ocular in situ gelling systems for which in vivo retention times were determined in sheep following in vitro characterization and cytotoxicity studies. In vivo results were then compared to commercially available Patanol eye drops. the transparent gels formulated using appropriate amounts of polymers and having longer ocular retention times appear to be a viable alternative to commercially available eye drops.
7 December 2023 in Fabad Journal of Pharmaceutical Sciences
The purpose of the study is to develop metronidazole (MET) containing microemulsion systems for topical application, to overcome limitations of local antibacterial treatments. For preparation of drug loaded microemulsions pseudo-phase diagram technique was applied; IPP as oil phase, Span 80 and Cremophor EL as surfactant, ethanol and propylene glycol as co-surfactant and distilled water was used as aqueous phase. Globule size ranging between 126.82.8 to 150.81.6 nm and PDI between 0.210.02 to 0.350.06 were obtained. Zeta potentials of the formulations measured as 0.480.08 – 0.680.14 mV and conductivity was between 0.50.0 and 0.60.0, implicating the formation of w/o emulsions. A UPLC method was developed and validated according to the ICH Q2 (R1) guideline, for quantification of MET, and drug content was calculated as 99.180.08 – 99.330.12%. MET release of 80.620.86% for S1MET and 62.061.08% for S2MET formulations at 24h, indicated the control over the MET release by the microemulsions. After 3. and 6. months, there were no difference in physicochemical properties of microemulsions and MET release showed similar profile; implicating the good stability of formulations.
24 January 2022 in Mersin Üniversitesi Tıp Fakültesi Lokman Hekim Tıp Tarihi ve Folklorik Tıp Dergisi
Amaç: Çalışmamızda Calendula officinalis'in morfolojik değerlendirmesi ve geleneksel kullanımları verilmiştir. Hazırlanan Calendula officinalis ekstresinin topikal uygulabilmesi için taşıyıcı olarak kullanılabilecek mikroemülsiyon geliştirmesi amaçlanmıştır. Yöntem: Calendula officinalis'in bitki örnekleri botanik bahçesinden toplanmış ve herbaryuma yerleştirilmiştir. Üçgen faz diyagramları, yağ ve farklı oranlarda farklı yüzey aktif madde/yardımcı yüzey aktif maddenin kombinasyonları kullanılarak hazırlanıştır. Seçilen mikroemülsiyonların daha sonra damlacık boyutu, polidispersite indeksi, pH, zeta potansiyeli ve reoloji açısından karakterizasyonları yapılmıştır. Bulgular: Faz diyagramlarından elde edilen Calendula officinalis ekstresi yüklü kararlı mikroemülsiyonlar başarılı şekilde formüle edilmiştir. Geliştirilen formülasyonlar, 208.24 ± 2.28, 232.66 ± 4.46 ve 254.82 ± 6.84 nm damlacık boyutu, 0.22 ± 0.04, 0.27 ± 0.03 ve 0.26 ± 0.03, pH 5.40 ± 0.10, 5.62 ± 0.12 ve 5.58 ± 0.08 değerinde polidisperslik indeksi göstermiştir. Formülasyonlar şeffaf elde edilmiş ve nötr zeta potansiyel değeri göstermiştir. Mikroemülsiyonların bu çalışmada yüksek kararlılığa sahip oldukları görülmüştür. Sonuç: Calendula officinalis ekstresi yüklü mikroemülsiyon sistemin, sedef hastalığının klinik araştırmalarında ve topikal tedavisinde kullanılabilmesi için umut vaat edici bir ilaç taşıyıcı olabileceği düşünülmektedir.
30 April 2026 in Journal of Drug Delivery Science and Technology